The Power of Vascular Innovation

Imagine a readily available, “off the shelf ” bioengineered human acellular vessel (HAV) that could replace a patient’s own blood vessel or create new vascular access for patients who require dialysis, without requiring cells or tissue from the patient. Humacyte is making that happen.

WATCH NOW

Groundbreaking technology

Our unique process, paired with innovation and continued improvement and evolution, puts us at the forefront.

Investigational HAVs

Making a meaningful impact on patient care.

About Humacyte

Humacyte CEO Dr. Laura Niklason Presents at J.P. Morgan Healthcare Conference
https://tinyurl.com/y2ymqhvy
https://tinyurl.com/y2ymqhvyLaura Niklason, CEO
Entrepreneurial Journey
Oh, the Places Grads Go
Surgeons Perform First Bioengineered Blood Vessel Transplant in Military Patient
Get More News and Updates

Why Human Acellular Vessels (HAV)?

From lower costs to fewer operations, HAVs may offer critical benefits.

Explore the Benefits

Our path to success.

With each year, we’ve moved closer to lifesaving treatments.

Our Milestones

Join our team and make a difference.

Career Opportunities

We'd love to
hear from you.

Scroll to Top